Senate File 552 - Introduced SENATE FILE 552 BY COMMITTEE ON HEALTH AND HUMAN SERVICES (SUCCESSOR TO SSB 1138) A BILL FOR An Act relating to a review of anti-obesity medications by the 1 department of health and human services and the department 2 of administrative services for purposes of the medical 3 assistance program and health insurance plans for state 4 employees. 5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: 6 TLSB 1939SV (2) 91 lh/ko
S.F. 552 Section 1. ANTI-OBESITY MEDICATION REVIEW AND REPORT. For 1 purposes of the medical assistance program under chapter 249A 2 and health insurance plans for state employees established 3 pursuant to chapter 509A, the department of health and human 4 services and the department of administrative services shall 5 review anti-obesity medications, including GLP-1 agonists, 6 for effectiveness relating to weight loss, the impact 7 on comorbidities, the potential for cost savings due to 8 deferred medical procedures and reduced medications related 9 to comorbidity, recommended eligibility requirements, any 10 short-term and long-term costs associated with coverage, 11 and any other criteria the departments deem relevant. The 12 department of health and human services and the department of 13 administrative services shall submit a report to the general 14 assembly by January 5, 2026, with the departments findings, 15 proposed eligibility requirements, and any short-term and 16 long-term costs associated with coverage. 17 EXPLANATION 18 The inclusion of this explanation does not constitute agreement with 19 the explanations substance by the members of the general assembly. 20 This bill relates to the department of health and human 21 services (HHS) and the department of administrative services 22 (DAS) review of anti-obesity medication for purposes of the 23 medical assistance program and health insurance plans for state 24 employees established pursuant to Code chapter 509A. 25 The bill requires HHS and DAS to review anti-obesity 26 medications, including GLP-1 agonists, for effectiveness, 27 comorbidities, cost savings, eligibility requirements, and 28 short-term and long-term costs associated with coverage. HHS 29 and DAS shall submit a report to the general assembly by 30 January 5, 2026, containing HHSs and DASs findings, proposed 31 eligibility requirements, and any short-term and long-term 32 costs associated with coverage. 33 -1- LSB 1939SV (2) 91 lh/ko 1/ 1